

1 **Clinical and molecular characterization of the vinorelbine-platinum**
2 **chemotherapeutic regimen in HER2(-) metastatic breast cancer**

3

4 I-Wei Ho¹, Yi-Ru Tseng², Chun-Yu Liu^{1,3,4}, Yi-Fang Tsai^{3,4,5}, Chi-Cheng Huang^{3,4,5},
5 Ling-Ming Tseng^{3,4,5}, Ta-Chung Chao^{3,4,6}, Jiun-I Lai^{1,2,3}

6

7

8 ¹ Division of Medical Oncology, Department of Oncology, Taipei Veterans General
9 Hospital, Taipei, Taiwan

10 ² Institute of Clinical Medicine, National Yang-Ming Chiao Tung University,
11 Taipei, Taiwan

12 ³ Comprehensive Breast Health Center, Taipei Veterans General Hospital, Taipei,
13 Taiwan

14 ⁴ School of Medicine, College of Medicine, National Yang-Ming Chiao Tung
15 University, Taipei, Taiwan

16 ⁵ Division of Breast Surgery, Department of Surgery, Taipei Veterans General Hospital,
17 Taipei, Taiwan

18 ⁶ Division of Cancer Prevention, Department of Oncology, Taipei Veterans General
19 Hospital, Taipei, Taiwan

20

21

22 Correspondence: Jiun-I Lai, M.D. Ph.D., jilai@nycu.edu.tw

23

24

25

26

27

28

29

30

1 **Abstract:**

2 **Introduction**

3 Despite rapidly improving therapeutics, challenges remain in treatment of advanced
4 breast cancer. Vinorelbine, a semisynthetic vinca alkaloid, is effective and
5 well-tolerated in breast cancer treatment. The combination of vinorelbine and
6 platinum-combination is a well-tolerated but underreported chemotherapy regimen.
7 Bevacizumab, a VEGF-neutralizing antibody, has shown efficacy in HER2-negative
8 metastatic breast cancer (mBC) when combined with chemotherapy. In this study we
9 aim to investigate the clinical and molecular effects of vinorelbine-platinum in heavily
10 pretreated HER2-negative mBC, as well as the role of addition of bevacizumab.

11 **Material and methods**

12 We conducted a retrospective study at Taipei Veterans General Hospital to evaluate the
13 effectiveness of the vinorelbine-platinum regimen in heavily pretreated
14 HER2-negative mBC patients from 2016 to 2020, with a portion of patients receiving
15 additional bevacizumab. To model the molecular perturbations at a cellular level,
16 transcriptional profiling of a triple negative breast cancer cell line treated with
17 cisplatin-vinorelbine was done by RNA-sequencing.

18 **Results**

19 The cohort included 54 patients. 50% of the patients received ≥ 5 lines of systemic
20 treatment in the metastatic setting. All the patients had received anthracyclines and
21 taxane. In patients treated with vinorelbine-platinum combination, the median
22 progression-free survival (PFS) and overall survival (OS) were 2.3 and 7.3 months,
23 respectively. With bevacizumab, median PFS improved to 4.1 months. Objective
24 response rate (ORR) and disease control rate (DCR) without bevacizumab were
25 11.1% and 27.7%, respectively, improving to 25% and 83.3% with bevacizumab.
26 Adverse events occurred in 37.0% of patients, with no grade IV events reported.
27 Transcriptional profiling revealed significant downregulation of MAPK pathway,
28 angiogenesis, and growth factor signaling related genes.

29 **Conclusion**

30 The vinorelbine-platinum regimen, particularly with bevacizumab, shows efficacy
31 even in heavily pretreated HER2-negative metastatic breast cancer patients. Molecular
32 analyses of treated cells highlight potential targets and mechanisms of action,
33 providing a basis for future therapeutic strategies.

34

35 **Keywords: platinum, vinorelbine, metastatic breast cancer, bevacizumab, MAPK**

1 **Introduction**

2 Breast cancer is one of the most prevalent malignancies in the world, with more
3 than 2.3 million newly diagnosed cases and 665,000 deaths globally in 2022.[1]
4 Outcomes for breast cancer has improved drastically in the past 2 decades, with huge
5 strides in all three major subtypes (Hormone receptor (HR) positive, HER2 positive,
6 triple negative (TNBC)). Even in metastatic disease, overall survival reaches 4-5 years
7 due to the advent of CDK4/6 inhibitors in HR(+) metastatic breast cancer (mBC)[2],
8 dual blockade with pertuzumab plus trastuzumab[3]. With metastatic TNBC, overall
9 survival (OS) reaches 2 years in PD-L1 high tumors with
10 immunotherapy-chemotherapy combination [4], a huge improvement from
11 prior-immunotherapy era, but nonetheless much worse outcome compared to HR(+)
12 and HER2(+) subtypes. Overall, five-year survival rates in patient with metastatic
13 breast cancers has been reported to be about 30% [5], although novel therapies are
14 constantly improving this statistic. However, even with these highly efficacious
15 regimens that prolonged overall survival, resistance eventually occurs, and in patients
16 who have progressed on multiple systemic agents, therapeutic options are more
17 limited.

18
19 Vinorelbine, a synthetic vinca alkaloid chemotherapeutic agent, disrupts
20 microtubule formation during mitosis.[6] Due to its efficacy, well tolerability, and low
21 toxicity or adverse effects, vinorelbine is commonly used in advanced metastatic
22 breast cancer and is often the drug of choice in fragile or palliative settings.[7, 8]
23 Vinorelbine is an integral component of metronomic therapy for breast cancer[9], and
24 has even shown superior efficacy to weekly paclitaxel in a phase 2 trial [10].The role
25 of platinum agents, such as cisplatin and carboplatin, is well established in breast
26 cancer, particularly in TNBC. Platinum drugs are now recognized as standard of care
27 in the neoadjuvant immunooncology treatment of non-metastatic TNBC, in the
28 neoadjuvant setting without immunotherapy, and in metastatic TNBC (mTNBC)
29 patients with BRCA1/2 mutations. [11-13] The combination of vinorelbine and
30 platinum is a commonly used regimen in lung cancer[14], but its use in breast cancer
31 is relatively less reported since 2 decades ago[15, 16]. This prompted us to ask
32 whether vinorelbine plus platinum would be a tolerable regimen for heavily pretreated
33 patients while maintaining acceptable toxicity profile.

1

2 Angiogenesis is recognized as a critical factor in the progression of metastatic
3 breast cancer. [17] Elevated serum levels of vascular endothelial growth factor (VEGF)
4 in patients with metastatic breast cancer have been associated with inferior clinical
5 outcomes.[18] Bevacizumab, a VEGF neutralizing antibody, plays a critical role in
6 inhibiting neoplastic angiogenesis, effectively impeding tumor progression.[19]
7 Previous meta-analyses have established the efficacy of bevacizumab in treating
8 HER2 negative metastatic breast cancer when used in conjunction with chemotherapy,
9 resulting in improvements in progression-free survival (PFS) and objective response
10 rate (ORR).[20] The addition of bevacizumab to chemotherapy in first line HER2 (-)
11 metastatic breast cancer resulted in improved PFS (9.2 months) and response rate
12 (49%) [21], and benefit was especially observed in poor prognosis patient groups
13 including TNBC patients.

14

15 In our study, we aimed to investigate the clinical outcomes of
16 platinum-vinorelbine regimen, especially in heavily pre-treated patients. In our cohort,
17 50% patients had received five or more lines of systemic therapy in the metastatic
18 setting. We observed that the addition of bevacizumab increased PFS, response rate,
19 and more importantly clinical benefit rate (CBR) to up to 83.3%, which is an
20 important treatment goal in heavily pretreated patients. Transcriptional profiling
21 revealed changes in gene expression profiles elicited by platinum-vinorelbine regimen,
22 and interestingly revealed a potential synergy mechanism for bevacizumab. Our study
23 provides molecular insight to complement clinical observations for a potentially
24 useful regimen for a salvage chemotherapy setting.

25

26 **Material and methods**

27 **Study Design and Setting:**

28 This retrospective cohort study was conducted at Taipei Veterans General
29 Hospital in Taiwan, aiming to evaluate the efficacy of salvage chemotherapy regimens
30 that involved the vinorelbine-platinum combination. The study also aimed to compare
31 treatment responses, progression-free survival, overall survival, prognostic factors, and
32 potential adverse outcomes. Specifically, the study focused on patients with HER2
33 negative metastatic breast cancer who underwent salvage chemotherapy between the

1 years 2016 March and 2020 December. The investigation also explored the impact of
2 incorporating bevacizumab into the treatment regimen. Data for this study were
3 obtained from the electronic medical records. The extracted data encompassed a
4 comprehensive range of information, including vital signs, symptoms, investigation
5 procedures, workup details, diagnostic results, and patient management. Individuals
6 lacking a confirmed diagnosis through histopathology verification or those referred to
7 other hospitals for chemotherapy were excluded from the study. To define HER2
8 negativity, it was based on a HER2 result of 1+ or 0 in immunohistochemistry. In
9 instances where the HER2 result was 2+, it was categorized as negative if paired with
10 a negative outcome in the fluorescence in situ hybridization (FISH) test. Alongside
11 chemotherapy details, we assessed age at breast cancer diagnosis, metastases sites,
12 prior chemotherapy, treatment sequence, and adverse events. Institutional Review
13 Board (IRB) approval for this research was secured from Taipei Veterans General
14 Hospital (IRB TPEVGH No. 2023-09-007BC).

15 Overall response rate (ORR), disease control rate (DCR), progression-free
16 survival (PFS) and overall survival (OS) were assessed according to the Response
17 Evaluation Criteria in Solid Tumors (RECIST) v. 1.1 criteria. [22] Adverse events
18 were also collected. Overall survival (OS) was defined as the period from the start of
19 vinorelbine-platinum chemotherapy to the patient's death from any cause. PFS was
20 measured from the initiation of vinorelbine-platinum to the development of
21 progressive disease (PD) or death.

22

23 **Statistical analysis:**

24 Statistical analysis was conducted using SPSS v26. All p-values were considered
25 two-sided, and statistical significance was defined as $p < 0.05$. Survival curves were
26 generated using the Kaplan-Meier method. Attributes related to the study were subject
27 to univariate analysis and multivariate analysis to ascertain their association with PFS
28 and OS. For both univariate and multivariate evaluations of prognostic factors
29 pertaining to PFS and OS, the Cox proportional hazards model was applied. The
30 outcomes were presented using hazard ratios (HR) as indicators of survival decline,
31 along with their corresponding 95% confidence intervals.

32

33 **Cell culture and drug treatment**

34 The hormone positive breast cancer cell lines MDA-MB-231 (purchased from ATCC

1 Cell Lines (<https://www.atcc.org/>) were maintained in Dulbecco's Modified Eagle
2 Medium (DMEM, Gibco) respectively. All culture medium contained 10% Fetal
3 Bovine Serum (FBS, Gibco) and 1% Penicillin Streptomycin (P/S, Gibco). Cells were
4 incubated in 37°C, 5% CO₂ under standard molecular biology conditions. Vinorelbine
5 and cisplatin were purchased from Sigma-Aldrich (Missouri, United States) and
6 diluted, stored per manufacturer instructions until use in cell culture.

7

8 **RNA-sequencing**

9 MDA-231 cells (5 to 7 x 10⁵ per well) were seeded onto 6 cm dish and treated with
10 7µM cisplatin + 14µM vinorelbine or vehicle (DMSO) for 24 hours, washed in PBS,
11 and RNA was extracted (Total RNA Isolation Kit, NovelGene). RNA was checked for
12 quantity with a Nano-Drop (Thermo Fisher Scientific, RNA with A260/A280 ratios
13 over 1.9 were used.) than stored at -80°C. Libraries were prepared using a TruSeq
14 Stranded mRNA sample preparation kit (Illumina, San Diego, CA) from 500 ng of
15 purified total RNA according to the manufacturer's protocol in a reduced reaction
16 volume. The finished cDNA libraries were assessed for quality using a Bioanalyzer
17 and quantified with a Quant-iT dsDNA Assay kit (Thermo Fisher Scientific, Waltham,
18 MA). The uniquely indexed libraries were multiplexed based on this quantitation and
19 the pooled sample was quantified by qPCR using the Kapa Biosystems (Wilmington,
20 MA) library quantification kit by the Molecular Biology Core Genomics Facility at
21 the Dana-Farber Cancer Institute and sequenced on Illumina NovaSeq 6000 run with
22 paired-end reads. Reads were processed to counts using the bcbio-Nextgen toolkit
23 version 1.0.3a (<https://github.com/chapmanb/bcbio-nextgen>) as follows: (1) Reads
24 were trimmed and clipped for quality control in cutadapt v1.12; (2) Read quality was
25 checked for each sample using FastQC 0.11.5; (3) High-quality reads were then
26 aligned into BAM files through STAR 2.5.3a using the human assembly GRCh37; (4)
27 BAM files were imported into DEXSeq-COUNT 1.14.2 and raw counts TPM and
28 RPKM were calculated. R package edgeR (McCarthy et al., 2012; Robinson et al.,
29 2010) 3.18.1 (R version 3.2.1) was used for differential analysis and generate log fold
30 change, p value and FDR.

31 The RNA-seq results were deposited into the Gene Expression Omnibus (GEO)
32 database under the accession number GSE267621.

33

34 **Pathway analysis and data processing**

1 Heatmaps, gene ontology (GO) analysis, were generated by the R packages
2 “ClusterProfiler”, “enrichplot”, “ComplexHeatmap”. DAVID analysis was performed on
3 the DAVID website (<https://david.ncifcrf.gov/tools.jsp>[23]).
4
5

6 **Results**

7 **1. Clinical characteristics of a HER2 negative metastatic breast cancer cohort**

8 A total of 54 patients diagnosed with HER2 negative metastatic breast cancer and
9 treated with the vinorelbine/platinum regimen were included in the study. The baseline
10 characteristics of these patients are detailed in **Table 1**. The entire cohort comprised of
11 female participants. The average age was 57.2 ± 8.7 years. Among them, 35 patients
12 (64.8%) exhibited ER and/or PR positivity, while 19 patients (35.2%) were
13 categorized as triple negative. More than 60% of patients had either bone, lung, or
14 liver metastases, reflecting a cohort with heavy disease burden. All patients had
15 received prior treatment with anthracyclines and taxane. 50% of all patients had
16 previously received more than five lines of chemotherapy. 20 patients (37%) were de
17 novo metastatic disease upon diagnosis, while 63% were recurrent disease. Other
18 clinical details are described in **table 1**.
19

20 **2. Clinical efficacy and adverse effects of the platinum plus vinorelbine, with or** 21 **without addition of bevacizumab**

22
23 **Table 2** presents the clinical efficacy data. The median progression-free survival
24 (PFS) was recorded at 2.3 months, while the median overall survival (OS) was 7.3
25 months. With the addition of bevacizumab, median PFS was extended to 4.1 months
26 (hazard ratio (HR) 0.54, $p = 0.04$), and OS increased to 12.4 months. Among the
27 patients, 11.1% (6/54) achieved a partial response (PR), 16.7% (9/54) exhibited stable
28 disease (SD), and 72.2% (39/54) demonstrated progressive disease (PD). The
29 calculated rates for objective response (ORR) and disease control (DCR) were 11.1%
30 and 27.7%, respectively; and was increased to 25% and DCR to 83.3%, respectively.
31 Interestingly, TNBC patients had a longer median OS (12 months), while HR(+)
32 patients had an OS of 6.6 months.

33 Univariate analysis results are presented in **table 3**. Age > 65 and brain

1 metastases were significantly associated with increased hazard ratio (HR) for PFS,
2 while addition of bevacizumab significantly decreased HR for progression (HR=0.51,
3 confidence interval (CI) 0.26-0.98, p=0.045). Age \geq 65, presence of lung metastasis,
4 and prior treatment of \geq 5 lines of chemotherapy were significantly associated with
5 increased HR for overall survival. In our data, addition of bevacizumab did not
6 significantly prolong OS.

7 The findings from the multivariate analyses, shown in **table 4**, indicated that the prior
8 treatment of \geq 5 lines of chemotherapy was significantly associated with both
9 decreased OS and PFS. Additionally, lung metastasis was significantly associated with
10 reduced OS.

11 Of the total 54 patients, 12 (22.2%) received additional bevacizumab treatment.
12 Both univariate analysis (**Table 3**) and Kaplan-Meier plots (**Figures 1a and 1b**)
13 demonstrated a significant benefit in PFS associated with the addition of bevacizumab,
14 although no significant improvement in OS was observed.

15 Within our cohort of 54 patients, \geq grade 3 adverse events were documented in 20
16 individuals (37.0%), described in **Table 5**. Most of the adverse effects were related to
17 bone marrow toxicity, including grade III neutropenia accounted for 25.9% of cases,
18 and grade III anemia in 12.5%. Importantly, no grade IV adverse events were reported
19 in the study.

20

21 **3. Transcriptional profiling of triple negative breast cancer cells treated with** 22 **cisplatin-vinorelbine reveals molecular insights of cytotoxic mechanisms**

23

24 To model the molecular perturbations by cisplatin-vinorelbine combination, we treated
25 the triple negative breast cancer MDA-MB-231 cell line with a combination of
26 cisplatin plus vinorelbine, in comparison to vehicle treatment. Total RNA extracted
27 from treated cells underwent RNA-sequencing for transcriptional profiling.

28 Differential expression genes (DEGs) were analyzed for enriched pathways. We
29 observed that in gene ontology (GO) analysis, cisplatin-vinorelbine combination
30 resulted in strong impact of growth factor binding, PDGFR binding, TGF-beta binding,
31 as well as other pathways (**Fig 2A**). In pathway analysis by DAVID, the top enriched
32 pathways were the MAPK pathway and the Ras signaling pathway (**Fig 2B**). Heat map
33 analysis of the differentially expressed genes from the MAPK pathway revealed

1 downregulation in several growth factors, including EGF, CSF1, NGFR1, TGFA,
2 VEGFA, and CSF1R (**Fig 2C**), suggesting that platinum-vinorelbine regimen resulted
3 in transcriptional suppression of many tumors related growth factor signaling
4 pathways.

5

6 **Discussion**

7 Despite rapidly increasing therapy options in metastatic breast cancer, treatment
8 options for heavily pretreated patients are limited and clinical efficacy is usually
9 modest. In a real-world study using the Flatiron electronic database, the researchers
10 used the criteria for MONARCH 1 to investigate outcome in a highly pretreated
11 setting[24]. The investigators selected female HR (+) HER2(-) mBC patients who
12 received monotherapy using eribulin, vinorelbine, gemcitabine, capecitabine. These
13 patients had an ECOG performance status of 0-1. In this cohort containing 108
14 patients, median OS was 13.6 months. In a retrospective study of 78 prior treated mBC
15 (> 2 lines) patients who received eribulin monotherapy, the median PFS was 3 months,
16 and median OS was 7 months [25]. This study has efficacy data more similar to our
17 study, in a cohort of heavily pretreated patients with modest survival outcomes but
18 acceptable toxicity profile and tolerability. In patients heavily pretreated or unfit for
19 intensive chemotherapy, metronomic chemotherapy is often employed and offers
20 modest response rates and survival outcomes, while offering improved clinical benefit
21 rate (CBR)[26].

22

23 To date, the optimal first-line regimen for metastatic TNBC consists of
24 chemotherapy with or without immunotherapy or PARP inhibitors, depending on
25 PD-L1 expression and germline BRCA mutation status. Following the failure of
26 first-line therapy, sacituzumab govitecan is has shown benefit as later line
27 treatment.[27, 28] However, besides Sacituzumab govitecan, there is no clear
28 consensus on the optimal chemotherapy regimen for metastatic TNBC. Eribulin,
29 capecitabine, ixabepilone, and platinum-based therapies are all considered reasonable
30 options, yet no single regimen is regarded as superior in this setting.[27] Currently,
31 metastatic TNBC remains incurable. This area of research represents a significant
32 unmet clinical need, with novel therapeutic agents and combinations urgently required.
33 In our study, we observed that although PFS was similar between TNBC and HR(+),

1 OS was markedly increased in TNBC (12 months). Although the sample size is small,
2 our study provides interesting insights that is in line with previous reports that addition
3 of bevacizumab may be beneficial in metastatic TNBC. In the ATHENA study, the
4 TNBC subgroup when receiving 1st line bevacizumab plus chemotherapy had a time to
5 progression of 7.2 months and OS of 18.3 months, with an overall response rate of
6 49% [29]. Complemented with our RNA-seq data, our study suggests that
7 bevacizumab addition should be considered in TNBC patients for achieving better
8 disease control status.

9
10 The combination of vinorelbine and platinum has demonstrated efficacy against
11 TNBC in previous observational studies, even in heavily pretreated patients. [30, 31]
12 Our study extends these findings, showing efficacy in both TNBC and hormone
13 receptor-positive patients, with an objective response rate (ORR) of 11.1% and a
14 disease control rate (DCR) of 27.7%. Furthermore, co-administration with
15 bevacizumab enhanced these outcomes, elevating the ORR to 25% and the DCR to
16 83.3%. interestingly, both univariable and multivariable analyses consistently pointed
17 towards patients who had undergone 5 or more lines of chemotherapy experiencing
18 reduced PFS and OS. This aligns with earlier research, which demonstrated a decline
19 in clinical benefit rate from 85% in the initial line to 54% by the fourth line of
20 treatment.[32] It is noteworthy that the response rate in our study was lower compared
21 to prior studies. [30, 31] , but it must be taken into account that half of the patients in
22 our cohort received more than five lines of prior systemic therapy. Considering the
23 heavily treated nature of our cohort, it remains impressive that in such frail and
24 refractory patient group, the addition of bevacizumab to vinorelbine/platinum could
25 improve the response rate to 25%, with a very high disease control rate. Our cohort,
26 although with small sample size, suggests a promising combination especially in late
27 stage, refractory patients.

28
29 The MAPK signaling pathway plays a crucial role in breast cancer development,
30 particularly influencing the expression of estrogen receptor (ER), progesterone
31 receptor (PR), and HER2. It is closely associated with the invasion, metastasis, and
32 prognosis of TNBC.[33] Elevated MAPK activity correlates with shorter survival
33 times in TNBC patients, suggesting its potential as a prognostic indicator.[33, 34]
34 Various mitogens such as TGF- α , EGF, VEGF, and PDGF- β bind to their respective

1 receptors, triggering RAS activation, which subsequently stimulates the MAPK
2 pathway.[35] In our RNA sequencing analysis of triple-negative breast cancer cell
3 lines treated with a cisplatin-vinorelbine combination, we observed downregulation of
4 the MAPK pathway. Interestingly, VEGF-A was shown to be upregulated after
5 cisplatin/vinorelbine treatment. This suggested a rationale for combination therapy
6 with cisplatin/vinorelbine and bevacizumab, enhancing the VEGF-A targeting efficacy
7 of bevacizumab. More preclinical and clinical studies will shed light on this issue,
8 whether VEGF-A serum concentrations are correlated with treatment outcome of this
9 regimen, and whether anti-angiogenesis activity is impaired. Notably, targeting various
10 steps in the MAPK pathway with BRAF plus MEK inhibitors has been established as
11 the standard of care for patients with advanced-stage melanoma harboring BRAF
12 V600 mutations.[36] MEK inhibitor Trametinib has been proposed to possess activity
13 towards TNBC in phase 2 study.[37] We hypothesize that combining this approach
14 with bevacizumab could yield synergistic antitumor effects through vertical inhibition.
15 Interestingly, our RNA-seq data revealed that many of the aforementioned growth
16 factors pathways are downregulated by treatment of platinum-vinorelbine, suggesting
17 promising clinical activity for further consideration.

18
19 It is important to acknowledge that our study had a limited sample size, thus
20 drawing definitive conclusions regarding the specific characteristics for the
21 vinorelbine-platinum regimen is challenging. Further investigations with larger cohorts
22 are warranted to pinpoint which patient groups can derive significant benefits from the
23 vinorelbine-platinum regimen. However, we believe that our study provides valuable
24 insights into a cohort with an extremely poor prognosis and limited clinical options,
25 contributing preliminary data that could guide further development of systemic
26 therapies. Given that vinorelbine targets microtubules, other anti-microtubule agents
27 such as eribulin, ixabepilone, and taxane also play significant roles, not only in
28 first-line but even in heavily pretreated patients.[27, 38, 39] It is intriguing to speculate
29 that newer agents, such as antibody-drug conjugates with tubule-targeting payloads
30 like enfortumab vedotin, may demonstrate clinical activity in metastatic TNBC, with
31 or without the addition of bevacizumab.[40]

32

33 **Conclusions**

1 The vinorelbine/platinum regimen, particularly when combined with bevacizumab,
2 demonstrates efficacy in heavily pretreated HER2-negative metastatic breast cancer
3 patients. Adverse events associated with this treatment were manageable. Molecular
4 analyses of treated cells have identified potential targets and mechanisms of action,
5 laying the groundwork for the development of future therapeutic strategies.

6

7 **Figure legends:**

8 Table 1: Clinical characteristics of patients receiving platinum-vinorelbine regimen

9 Table 2: Clinical outcomes of patients receiving platinum-vinorelbine regimen

10 Table 3-4: univariate (Table 3) and multivariate (Table 4) analysis of relevant clinical
11 factors for PFS and OS

12 Table 5: prevalence of adverse effects with platinum-vinorelbine regimen

13 Fig 1A-B: Kaplan Meier plots of all patients are shown for a) progression-free survival
14 with/without Bevacizumab b) overall survival with/without Bevacizumab

15 Fig 2A: gene ontology (GO) analysis of platinum-vinorelbine regimen treatment in
16 TNBC cells

17 Fig 2B: DAVID analysis of RNA-seq differentially expressed genes (DEG)

18 Fig 2C: heatmap comparing differentially changed genes in the MAPK pathway
19 between platinum-vinorelbine treated cells and DMSO treated cells. vin_cis:
20 vinorelbine plus cisplatin treated cells. 2 biological repeats were done for each
21 treatment condition.

22

23 **Acknowledgements**

24 Funding: This study was partially funded by the grants to JIL: NSTC 112-2314-B-A49
25 -054 (National Science and Technology Council, Taiwan), the Taiwan Clinical
26 Oncology Research Foundation, the Melissa Lee Cancer Foundation, and
27 112DHA0100294 (Taipei Veterans General Hospital internal grant)

28

29

30 **Reference:**


31 1. Bray, F., et al., *Global cancer statistics 2022: GLOBOCAN estimates of incidence*
32 *and mortality worldwide for 36 cancers in 185 countries*. CA Cancer J Clin,
33 2024.


34 2. Hortobagyi, G.N., et al., *Overall Survival with Ribociclib plus Letrozole in*


- 1 *Advanced Breast Cancer*. N Engl J Med, 2022. **386**(10): p. 942-950.
- 2 3. Swain, S.M., et al., *Pertuzumab, trastuzumab, and docetaxel in HER2-positive*
- 3 *metastatic breast cancer*. N Engl J Med, 2015. **372**(8): p. 724-34.
- 4 4. Schmid, P., S.Y. Chui, and L.A. Emens, *Atezolizumab and Nab-Paclitaxel in*
- 5 *Advanced Triple-Negative Breast Cancer. Reply*. N Engl J Med, 2019. **380**(10): p.
- 6 987-988.
- 7 5. Siegel, R.L., A.N. Giaquinto, and A. Jemal, *Cancer statistics, 2024*. CA Cancer J
- 8 Clin, 2024. **74**(1): p. 12-49.
- 9 6. Perez, E.A., *Microtubule inhibitors: Differentiating tubulin-inhibiting agents*
- 10 *based on mechanisms of action, clinical activity, and resistance*. Mol Cancer
- 11 Ther, 2009. **8**(8): p. 2086-95.
- 12 7. Montagna, E., et al., *The prolonged clinical benefit with metronomic*
- 13 *chemotherapy (VEX regimen) in metastatic breast cancer patients*. Anticancer
- 14 Drugs, 2022. **33**(1): p. e628-e634.
- 15 8. Liu, C.T., et al., *Metronomic vinorelbine is an excellent and safe treatment for*
- 16 *advanced breast cancer: a retrospective, observational study*. J Cancer, 2021.
- 17 **12**(17): p. 5355-5364.
- 18 9. Montagna, E., et al., *Metronomic Chemotherapy for First-Line Treatment of*
- 19 *Metastatic Triple-Negative Breast Cancer: A Phase II Trial*. Breast Care (Basel),
- 20 2018. **13**(3): p. 177-181.
- 21 10. Munzone, E., et al., *Efficacy of Metronomic Oral Vinorelbine,*
- 22 *Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in*
- 23 *Patients With Estrogen Receptor-Positive, ERBB2-Negative Metastatic Breast*
- 24 *Cancer: Final Results From the Phase 2 METEORA-II Randomized Clinical Trial*.
- 25 JAMA Oncol, 2023. **9**(9): p. 1267-1272.
- 26 11. Poggio, F., et al., *Platinum-based neoadjuvant chemotherapy in*
- 27 *triple-negative breast cancer: a systematic review and meta-analysis*. Ann
- 28 Oncol, 2018. **29**(7): p. 1497-1508.
- 29 12. Schmid, P., et al., *Pembrolizumab for Early Triple-Negative Breast Cancer*. New
- 30 England Journal of Medicine, 2020. **382**(9): p. 810-821.
- 31 13. Tutt, A., et al., *Carboplatin in BRCA1/2-mutated and triple-negative breast*
- 32 *cancer BRCAness subgroups: the TNT Trial*. Nat Med, 2018. **24**(5): p. 628-637.
- 33 14. Provencio, M., et al., *Cisplatin plus oral vinorelbine as first-line treatment for*
- 34 *advanced non-small-cell lung cancer: a prospective study confirming that the*
- 35 *day-8 hemogram is unnecessary*. Clin Transl Oncol, 2013. **15**(8): p. 659-64.
- 36 15. Shamseddine, A.I., et al., *Combination cisplatin-vinorelbine for relapsed and*
- 37 *chemotherapy-pretreated metastatic breast cancer*. Am J Clin Oncol, 1999.
- 38 **22**(3): p. 298-302.

- 1 16. Sharma, R.A., et al., *Reversibility of liver failure secondary to metastatic breast*
2 *cancer by vinorelbine and cisplatin chemotherapy*. *Cancer Chemother*
3 *Pharmacol*, 2003. **52**(5): p. 367-70.
- 4 17. Harry, J.A. and M.L. Ormiston, *Novel Pathways for Targeting Tumor*
5 *Angiogenesis in Metastatic Breast Cancer*. *Frontiers in Oncology*, 2021. **11**.
- 6 18. Banys-Paluchowski, M., et al., *The clinical relevance of serum vascular*
7 *endothelial growth factor (VEGF) in correlation to circulating tumor cells and*
8 *other serum biomarkers in patients with metastatic breast cancer*. *Breast*
9 *Cancer Res Treat*, 2018. **172**(1): p. 93-104.
- 10 19. Marty, M. and X. Pivot, *The potential of anti-vascular endothelial growth*
11 *factor therapy in metastatic breast cancer: clinical experience with*
12 *anti-angiogenic agents, focusing on bevacizumab*. *Eur J Cancer*, 2008. **44**(7): p.
13 912-20.
- 14 20. Sun, Z., et al., *Efficacy of bevacizumab combined with chemotherapy in the*
15 *treatment of HER2-negative metastatic breast cancer: a network*
16 *meta-analysis*. *BMC Cancer*, 2020. **20**(1): p. 180.
- 17 21. Miles, D.W., et al., *First-line bevacizumab in combination with chemotherapy*
18 *for HER2-negative metastatic breast cancer: pooled and subgroup analyses of*
19 *data from 2447 patients*. *Ann Oncol*, 2013. **24**(11): p. 2773-80.
- 20 22. Eisenhauer, E.A., et al., *New response evaluation criteria in solid tumours:*
21 *revised RECIST guideline (version 1.1)*. *Eur J Cancer*, 2009. **45**(2): p. 228-47.
- 22 23. Sherman, B.T., et al., *DAVID: a web server for functional enrichment analysis*
23 *and functional annotation of gene lists (2021 update)*. *Nucleic Acids Res*, 2022.
24 **50**(W1): p. W216-w221.
- 25 24. Rugo, H.S., et al., *Real-world survival outcomes of heavily pretreated patients*
26 *with refractory HR+, HER2-metastatic breast cancer receiving single-agent*
27 *chemotherapy-a comparison with MONARCH 1*. *Breast Cancer Res Treat*, 2020.
28 **184**(1): p. 161-172.
- 29 25. Mandal, T.K., et al., *Eribulin in heavily pretreated metastatic breast cancer: A*
30 *real-world data from India*. *Annals of Oncology*, 2020. **31**: p. s1264.
- 31 26. Fedele, P., et al., *Efficacy and safety of low-dose metronomic chemotherapy*
32 *with capecitabine in heavily pretreated patients with metastatic breast cancer*.
33 *Eur J Cancer*, 2012. **48**(1): p. 24-9.
- 34 27. Gennari, A., et al., *ESMO Clinical Practice Guideline for the diagnosis, staging*
35 *and treatment of patients with metastatic breast cancer*. *Ann Oncol*, 2021.
36 **32**(12): p. 1475-1495.
- 37 28. Bardia, A., et al., *Sacituzumab Govitecan in Metastatic Triple-Negative Breast*
38 *Cancer*. *N Engl J Med*, 2021. **384**(16): p. 1529-1541.

- 1 29. Thomssen, C., et al., *First-line bevacizumab-containing therapy for*
2 *triple-negative breast cancer: analysis of 585 patients treated in the ATHENA*
3 *study*. *Oncology*, 2012. **82**(4): p. 218-27.
- 4 30. Li, M., et al., *Vinorelbine Plus Platinum in Patients with Metastatic Triple*
5 *Negative Breast Cancer and Prior Anthracycline and Taxane Treatment*.
6 *Medicine (Baltimore)*, 2015. **94**(43): p. e1928.
- 7 31. Wang, J., et al., *Efficacy and Safety of Vinorelbine Plus Cisplatin vs.*
8 *Gemcitabine Plus Cisplatin for Treatment of Metastatic Triple-Negative Breast*
9 *Cancer After Failure with Anthracyclines and Taxanes*. *Med Sci Monit*, 2017.
10 **23**: p. 4657-4664.
- 11 32. Bakker, J.L., et al., *What is the benefit of treatment with multiple lines of*
12 *chemotherapy for patients with metastatic breast cancer? A retrospective*
13 *cohort study*. *Cancer Epidemiol*, 2015. **39**(6): p. 848-53.
- 14 33. Santen, R.J., et al., *The role of mitogen-activated protein (MAP) kinase in*
15 *breast cancer*. *J Steroid Biochem Mol Biol*, 2002. **80**(2): p. 239-56.
- 16 34. Gholami, S., et al., *Role of MAPK in oncolytic herpes viral therapy in*
17 *triple-negative breast cancer*. *Cancer Gene Ther*, 2014. **21**(7): p. 283-9.
- 18 35. Bahar, M.E., H.J. Kim, and D.R. Kim, *Targeting the RAS/RAF/MAPK pathway for*
19 *cancer therapy: from mechanism to clinical studies*. *Signal Transduct Target*
20 *Ther*, 2023. **8**(1): p. 455.
- 21 36. Robert, C., et al., *Improved overall survival in melanoma with combined*
22 *dabrafenib and trametinib*. *N Engl J Med*, 2015. **372**(1): p. 30-9.
- 23 37. Kun, E., et al., *MEK inhibitor resistance mechanisms and recent developments*
24 *in combination trials*. *Cancer Treat Rev*, 2021. **92**: p. 102137.
- 25 38. Cortes, J., et al., *Eribulin monotherapy versus treatment of physician's choice*
26 *in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label*
27 *randomised study*. *Lancet*, 2011. **377**(9769): p. 914-23.
- 28 39. Sparano, J.A., et al., *Randomized phase III trial of ixabepilone plus*
29 *capecitabine versus capecitabine in patients with metastatic breast cancer*
30 *previously treated with an anthracycline and a taxane*. *J Clin Oncol*, 2010.
31 **28**(20): p. 3256-63.
- 32 40. Bruce, J.Y., et al., *EV-202: A phase II study of enfortumab vedotin in patients*
33 *with select previously treated locally advanced or metastatic solid tumors*.
34 *Journal of Clinical Oncology*, 2020. **38**(15_suppl): p. TPS3647-TPS3647.
35







Term	Count	P Value	Fold Enrichment	FDR
MAPK signaling pathway	29	7.39E-06	2.568	6.8E-04
Ras signaling pathway	24	2.36E-05	2.710	1.3E-03
Rap1 signaling pathway	21	1.11E-04	2.665	4.7E-03
Lipid and atherosclerosis	18	0.003	2.231	4.1E-02
Legionellosis	8	0.005	3.807	5.7E-02
Alcoholic liver disease	13	0.007	2.440	7.0E-02

